Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Discovery Medicine|September 29, 2018
Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome itGulden Menderes, Salvatore Lopez, Chanhee Han, et al.
Discovery Medicine|July 19, 2018
Novel targeted therapies in ovarian and uterine carcinosarcomasChanhee Han, Gary Altwerger, Gulden Menderes, et al.
Gynecologic Oncology Reports|January 10, 2022
Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sitesJessie Y Li, Levent Mutlu, Joan Tymon-Rosario, et al.
American Journal of Clinical Oncology|March 23, 2021
Benefits of a Multidisciplinary Women's Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic RadiotherapyJessie Y Li, Johanna D'Addario, Joan Tymon-Rosario, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 14, 2014
Impact of body mass index on surgical outcomes and analysis of disease recurrence for patients with endometrial cancer undergoing robotic-assisted stagingGulden Menderes, Masoud Azodi, Lindsay Clark, et al.
Medical Oncology (Northwood, London, England)|April 12, 2017
Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivoGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Journal of Gynecologic Oncology|August 25, 2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional studyBurak Zeybek, Emily Webster, Natalia Pogosian, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 18, 2015
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitroFrancesca Ferrari, Stefania Bellone, Jonathan Black, et al.
Gynecologic Oncology Reports|February 2, 2018
Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancerBenjamin B Albright, Jonathan D Black, Rachel Passarelli, et al.
Gynecologic and Obstetric Investigation|January 3, 2019
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and OutcomesJacqueline Feinberg, Benjamin Albright, Jonathan Black, et al.
Pageof 8